Pegaptanib Sodium's Effect on Foveal Thickening in Exudative Subfoveal Age-Related Macular Degeneration
Data Collection
Eye Diseases+1
+ Macular Degeneration
+ Retinal Degeneration
Treatment Study
Summary
Study start date: March 1, 2004
Actual date on which the first participant was enrolled.This study focuses on treating a condition called Age-Related Macular Degeneration (AMD), specifically the exudative subfoveal type. AMD affects the macula, a small spot near the center of the retina, the light-sensitive tissue at the back of the eye. This study is important as it aims to find a more effective treatment for this condition, which is a common cause of vision loss in older adults. The study involves patients with different foveal thicknesses, a measure of the macula's condition. The study is designed as a randomized, double-masked trial, meaning neither the patients nor the doctors know who is receiving the treatment or a sham (fake) treatment. The treatment being tested is a drug called Pegaptanib Sodium, also known as Macugen. Some patients will receive Macugen, while others will receive a sham injection. After 24 weeks, all patients will start receiving Macugen until the end of the study at 54 weeks. The study's results will be measured by changes in the patients' vision and the thickness of their fovea.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.135 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 50 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria